SMARCB1 and synovial sarcoma: The chemical probes I-BRD9 and BI-7273 both showed some weak cytotoxic effect in SMARCB1-deficient MRT and synovial sarcoma but, importantly, only at a relatively high compound concentration of about 10 μM or higher, hinting at off-target activity of these inhibitors at high concentration [99].